{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:10:49Z","timestamp":1791281449094,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.beha.2004.03.003","type":"journal-article","created":{"date-parts":[[2004,5,31]],"date-time":"2004-05-31T15:09:05Z","timestamp":1086016145000},"page":"23-53","source":"Crossref","is-referenced-by-count":30,"title":["First-generation agents: aspirin, heparin and coumarins"],"prefix":"10.1016","volume":"17","author":[{"given":"Richard L","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2004.03.003_BIB1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/01.CIR.89.1.432","article-title":"History of drugs for thrombotic disease","volume":"89","author":"Mueller","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1098\/rstl.1763.0033","article-title":"An account of the success of the bark of the willow in the cure of agues","volume":"53","author":"Stone","year":"1763","journal-title":"Philosophical Transactions of the Royal Society of London [Biology]"},{"key":"10.1016\/j.beha.2004.03.003_BIB3","first-page":"38","article-title":"Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis","volume":"75","author":"Craven","year":"1953","journal-title":"Mississippi Valley Medical Journal"},{"key":"10.1016\/j.beha.2004.03.003_BIB4","first-page":"232","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nature"},{"key":"10.1016\/j.beha.2004.03.003_BIB5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(71)92108-8","article-title":"Effect of aspirin in amaurosis fugax","volume":"2","author":"Harrison","year":"1971","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB6","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","volume":"101","author":"Awtry","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB7","series-title":"Cardiovascular Pharmacotherapeutics","first-page":"323","author":"Frishman","year":"1997"},{"key":"10.1016\/j.beha.2004.03.003_BIB8","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1161\/01.CIR.103.12.1688","article-title":"Aspirin (5 mmol.L) inhibits leukocyte attack and triggered reactive cell proliferation in a 3D human coronary in vitro model","volume":"103","author":"Voisard","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11883-003-0046-6","article-title":"Post-stroke inflammatory response: effects of stroke evolution and outcome","volume":"5","author":"Tan","year":"2003","journal-title":"Current Atherosclerosis Reports"},{"key":"10.1016\/j.beha.2004.03.003_BIB10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/jcp.54.7.553","article-title":"Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians, and patients taking low dose aspirin","volume":"54","author":"Blacklock","year":"2001","journal-title":"Journal of Clinical Pathology"},{"key":"10.1016\/j.beha.2004.03.003_BIB11","series-title":"Aspirin","year":"2000"},{"key":"10.1016\/j.beha.2004.03.003_BIB12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of gastrointestinal hemorrhage with long term use of aspirin: meta-analysis","volume":"321","author":"Derry","year":"2000","journal-title":"British Medical Journal"},{"key":"10.1016\/j.beha.2004.03.003_BIB13","first-page":"3554","article-title":"The risk of bleeding complications with anti-platelet agents: a meta-analysis of 338,191 patients enrolled in 50 randomised controlled trials","volume":"106","author":"Serebruany","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"British Medical Journal"},{"key":"10.1016\/j.beha.2004.03.003_BIB15","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jama.280.22.1930","article-title":"Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials","volume":"280","author":"He","year":"1998","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.beha.2004.03.003_BIB16","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1067\/mob.2002.127376","article-title":"Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis","volume":"187","author":"Kozer","year":"2002","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1016\/j.beha.2004.03.003_BIB17","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0889-8529(02)00017-8","article-title":"Aspirin in diabetic retinopathy. A systematic review","volume":"31","author":"Bergerhoff","year":"2002","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"10.1016\/j.beha.2004.03.003_BIB18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bmj.308.6922.159","article-title":"Collaborative overview of randomised trials of anti-platelet therapy. II. Maintenance of vascular graft or arterial patency by anti-platelet therapy","volume":"308","year":"1994","journal-title":"British Medical Journal"},{"key":"10.1016\/j.beha.2004.03.003_BIB19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/bmj.308.6923.235","article-title":"Collaborative overview of randomised trials of anti-platelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by anti-platelet prophylaxis among surgical and medical patients","volume":"308","year":"1994","journal-title":"British Medical Journal"},{"key":"10.1016\/j.beha.2004.03.003_BIB20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of anti-platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"British Medical Journal"},{"key":"10.1016\/j.beha.2004.03.003_BIB21","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","article-title":"Platelet-active drugs. The relationships among dose, effectiveness, and side effects","volume":"119","author":"Patrono","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.beha.2004.03.003_BIB22","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.96.8.2751","article-title":"Aspirin as a therapeutic agent in cardiovascular disease","volume":"96","author":"Hennekins","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMcp012672","article-title":"Aspirin for primary prevention of coronary events","volume":"346","author":"Lauer","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-136-2-200201150-00016","article-title":"Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force","volume":"136","author":"Hayden","year":"2002","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB25","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17.187 cases of suspected acute myocardial infarction: ISIS-2","volume":"ii","year":"1988","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European stroke prevention study II: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"Journal of Neurological Science"},{"key":"10.1016\/j.beha.2004.03.003_BIB27","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","article-title":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial","volume":"355","year":"2000","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice","volume":"357","year":"2001","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB29","first-page":"233","article-title":"Thrombosis prevention trial: randomised trial of low intensity oral anti-coagulation with warfarin and low dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"251","year":"1998","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB30","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"251","author":"Hansson","year":"1998","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB31","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/archinte.163.17.2006","article-title":"An update on aspirin in the primary prevention of cardiovascular disease","volume":"163","author":"Eidelman","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/01.CIR.0000020190.45892.75","article-title":"AHA guidelines for primary prevention of cardiovascular disease and stroke: update","volume":"106","author":"Pearson","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB33","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa020798","article-title":"Aspirin and mortality from coronary bypass surgery","volume":"347","author":"Mangano","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0735-1097(10)80290-6","article-title":"Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis","volume":"19","author":"Roux","year":"1992","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB35","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1016\/j.beha.2004.03.003_BIB36","series-title":"Anti-platelet therapy for acute ischaemic stroke (Cochrane review)","author":"Sandercock","year":"2003"},{"key":"10.1016\/j.beha.2004.03.003_BIB37","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/01.STR.0000028456.18614.93","article-title":"Anti-coagulants and anti-platelet agents in acute ischemic stroke","volume":"33","author":"Coull","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.beha.2004.03.003_BIB38","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/hs1201.099384","article-title":"Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST)","volume":"32","author":"Wilterdink","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.beha.2004.03.003_BIB39","series-title":"Anti-platelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks (Cochrane review)","author":"Benavente","year":"2003"},{"key":"10.1016\/j.beha.2004.03.003_BIB40","series-title":"Sixth American College of Chest Physicians Consensus Conference on Anti-thrombotic Therapy","first-page":"1S","volume":"119","year":"2001"},{"key":"10.1016\/j.beha.2004.03.003_BIB41","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.0000037106.76139.53","article-title":"American Heart Association\/American College of Cardiology Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction","volume":"106","author":"Braunwald","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB42","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke","volume":"345","author":"Mohr","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB43","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the anti-platelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB44","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","article-title":"Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs","volume":"108","author":"Kurth","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB45","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(02)11138-X","article-title":"Effects of long term treatment with angiotensin converting enzyme inhibitors in the presence or absence of aspirin: a systematic review","volume":"360","author":"Teo","year":"2002","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB46","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB47","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0140-6736(99)05388-X","article-title":"Low dose and high dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial","volume":"353","author":"Taylor","year":"1999","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB48","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. Observations from the CURE study","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB49","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2141.2000.02267.x","article-title":"Relationship between bleeding time, aspirin and the PlA1\/A2 polymorphism of platelet glycoprotein IIIa","volume":"110","author":"Szczeklik","year":"2000","journal-title":"British Journal of Hematology"},{"key":"10.1016\/j.beha.2004.03.003_BIB50","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB51","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1152\/ajplegacy.1916.41.2.250","article-title":"The thromboplastic action of cephalin","volume":"41","author":"McLean","year":"1916","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB52","series-title":"Heparin sodium","year":"2000"},{"issue":"Suppl","key":"10.1016\/j.beha.2004.03.003_BIB53","doi-asserted-by":"crossref","first-page":"3H","DOI":"10.1016\/S0002-9149(03)00428-4","article-title":"Prothrombotic and anti-thrombotic pathways in acute coronary syndromes","volume":"91","author":"Selwyn","year":"2003","journal-title":"American Journal of Cardiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB54","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anti-coagulant therapy: heparin","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB55","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0038-1650255","article-title":"The effects of long-term heparin therapy during pregnancy on bone density","volume":"75","author":"Douketis","year":"1996","journal-title":"Thrombosis and Hemostasis"},{"key":"10.1016\/j.beha.2004.03.003_BIB56","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB57","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7326\/0003-4819-138-9-200305060-00008","article-title":"Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular weight heparin","volume":"138","author":"Raschke","year":"2003","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archinte.151.2.333","article-title":"A standard heparin nomogram for the management of heparin therapy","volume":"151","author":"Cruickshank","year":"1991","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB59","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.152.8.1589","article-title":"Optimal therapeutic level of heparin therapy in patients with venous thrombosis","volume":"152","author":"Hull","year":"1992","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB60","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","article-title":"The weight-based heparin dosing nomogram compared with a standard care nomogram: a randomized controlled trial","volume":"119","author":"Raschke","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","article-title":"Effect of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomised trial","volume":"353","year":"1999","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB62","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q wave myocardial infarction","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB63","doi-asserted-by":"crossref","first-page":"2239i","DOI":"10.1016\/S0735-1097(01)01345-6","article-title":"ACC\/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)","volume":"37","author":"Smith","year":"2001","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0038-1647289","article-title":"Quintavalla R.Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis: a randomized clinical trial","volume":"64","author":"Pini","year":"1990","journal-title":"Thrombosis and Hemostasis"},{"key":"10.1016\/j.beha.2004.03.003_BIB65","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anti-coagulant drugs in the treatment of pulmonary embolism: a controlled clinical trial","volume":"1","author":"Barritt","year":"1960","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB66","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(66)90822-1","article-title":"Heparin therapy in thromboembolic disease","volume":"1","author":"Kernohan","year":"1966","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB67","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(85)90459-3","article-title":"Need for long term anti-coagulant treatment in symptomatic calf-vein thrombosis","volume":"2","author":"Lagerstedt","year":"1985","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB68","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19.435 patients with acute ischemic stroke","volume":"349","year":"1997","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB69","series-title":"Anti-coagulants for acute ischemic stroke (Cochrane Review)","volume":"3","author":"Gubitz","year":"2003"},{"key":"10.1016\/j.beha.2004.03.003_BIB70","series-title":"Anti-coagulants versus anti-platelet agents for acute ischaemic stroke (Cochrane Review)","author":"Berge","year":"2003"},{"key":"10.1016\/j.beha.2004.03.003_BIB71","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJM198805053181805","article-title":"Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin","volume":"318","author":"Collins","year":"1988","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB72","doi-asserted-by":"crossref","first-page":"561","DOI":"10.7326\/0003-4819-96-5-561","article-title":"Reduction of mortality in general medical inpatients by low-dose heparin prophylaxis","volume":"96","author":"Halkin","year":"1982","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB73","series-title":"Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures (Cochrane review)","author":"Handoll","year":"2003"},{"key":"10.1016\/j.beha.2004.03.003_BIB74","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","year":"1990","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB75","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.276.10.811","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis","volume":"276","author":"Oler","year":"1996","journal-title":"Journal of the American Medical Association"},{"issue":"SII","key":"10.1016\/j.beha.2004.03.003_BIB76","first-page":"98","article-title":"Reductions in major morbidity and mortality by heparin in acute myocardial infarction","volume":"78","author":"MacMahon","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jama.268.2.240","article-title":"comparison of results of meta-analyses of randomised controlled trials and recommendations of clinical experts: treatments for myocardial infarction","volume":"268","author":"Antman","year":"1992","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.beha.2004.03.003_BIB78","first-page":"182","article-title":"Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction","volume":"2","year":"1989","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB79","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0140-6736(92)91893-D","article-title":"ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected myocardial infarction","volume":"339","year":"1992","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB80","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/bmj.313.7058.652","article-title":"Clinical effects of anti-coagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials","volume":"313","author":"Collins","year":"1996","journal-title":"British Medical Journal"},{"key":"10.1016\/j.beha.2004.03.003_BIB81","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0002-9149(97)89305-8","article-title":"Overview of randomised trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy","volume":"77","author":"Mahaffey","year":"1996","journal-title":"American Journal of Cardiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB82","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJM199011223232101","article-title":"A comparison between heparin and low dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction","volume":"323","author":"Hsia","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0268-9499(91)90073-D","article-title":"Thrombolysis and myocardial infarction","volume":"5","author":"Tiefenbrunn","year":"1991","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.beha.2004.03.003_BIB84","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1161\/01.CIR.100.9.1016","article-title":"Update: ACC\/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations","volume":"100","author":"Ryan","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB85","doi-asserted-by":"crossref","first-page":"1266i","DOI":"10.1016\/S0735-1097(01)01586-8","article-title":"ACC\/AHA\/ESC guidelines for the management of patients with atrial fibrillation","volume":"38","author":"Fuster","year":"2001","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB86","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/S0735-1097(98)00454-9","article-title":"ACC\/AHA guidelines for the management of patients with valvular heart disease","volume":"32","author":"Bonow","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB87","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB88","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.263.11.1513","article-title":"Anti-coagulation for noncardiac procedures in patients with prosthetic heart valves","volume":"263","author":"Eckman","year":"1990","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.beha.2004.03.003_BIB89","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199705223362107","article-title":"Management of anti-coagulation before and after elective surgery","volume":"336","author":"Kearon","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB90","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/01.CIR.0000066696.57519.AF","article-title":"Anti-platelet factor 4\/heparin antibodies. An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes","volume":"107","author":"Williams","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB91","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/0003-4819-136-3-200202050-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia","volume":"136","author":"Rice","year":"2002","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB92","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1023\/A:1019802310702","article-title":"Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate","volume":"19","author":"Malkov","year":"2002","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.beha.2004.03.003_BIB93","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1097\/00000539-200112000-00019","article-title":"A dose-determining trial of heparinase-I (Neutralase\u2122) for heparin neutralization in coronary artery surgery","volume":"93","author":"Heres","year":"2001","journal-title":"Anesthesia and Analgesia"},{"key":"10.1016\/j.beha.2004.03.003_BIB94","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1067\/mva.2001.112696","article-title":"Toma N.Heparin modulates integrin function in human platelets","volume":"33","author":"Sobel","year":"2001","journal-title":"Journal of Vascular Surgery"},{"key":"10.1016\/j.beha.2004.03.003_BIB95","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.290.12.1593","article-title":"Evaluation of prolonged anti-thrombotic pretreatment (cooling-off strategy) before intervention in patients with unstable coronary syndromes. A randomised trial","volume":"290","author":"Neumann","year":"2003","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.beha.2004.03.003_BIB96","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archinte.163.5.621","article-title":"Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis","volume":"163","author":"Hylek","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB97","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/135652b0","article-title":"Antihemorrhagic vitamin of the chick: occurrence and chemical nature","volume":"135","author":"Dam","year":"1935","journal-title":"Nature"},{"key":"10.1016\/j.beha.2004.03.003_BIB98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0021-9258(18)73076-7","article-title":"Studies of the hemorrhagic sweet clover disease: I. The preparation of hemorrhagic concentrates","volume":"136","author":"Campbell","year":"1940","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.beha.2004.03.003_BIB99","first-page":"433","article-title":"The anti-coagulants heparin and the dicoumarin 3,3\u2032-methylene-bis(-4-hydroxycoumarin)","volume":"18","author":"Prandoni","year":"1942","journal-title":"Bulletin of the New York Academy of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB100","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0002-8703(48)90278-6","article-title":"Report of the committee for the evaluation of anti-coagulants in the treatment of coronary thrombosis with myocardial infarction","volume":"36","author":"Wright","year":"1948","journal-title":"American Heart Journal"},{"key":"10.1016\/j.beha.2004.03.003_BIB101","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anti-coagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.beha.2004.03.003_BIB102","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMe020097","article-title":"Anti-thrombotic therapy after myocardial infarction","volume":"347","author":"Becker","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB103","series-title":"Coumarin and indandione derivatives","year":"2000"},{"key":"10.1016\/j.beha.2004.03.003_BIB104","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/01.CIR.0000060806.86686.EC","article-title":"Prosthetic heart valves and pregnancy","volume":"107","author":"Hung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/j.1875-9114.1997.tb03782.x","article-title":"A review of enzyme induction of warfarin metabolism with recommendations for patient management","volume":"17","author":"Cropp","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.beha.2004.03.003_BIB106","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-121-9-199411010-00009","article-title":"The interaction of warfarin with drugs and food: a critical review of the literature","volume":"121","author":"Wells","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB107","doi-asserted-by":"crossref","first-page":"108S","DOI":"10.1378\/chest.119.1_suppl.108S","article-title":"Hemorrhagic complications of anti-coagulant treatment","volume":"119","author":"Levine","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.beha.2004.03.003_BIB108","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","article-title":"American Heart Association\/American College of Cardiology foundation guide to warfarin therapy","volume":"107","author":"Hirsh","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB109","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.1378\/chest.119.1_suppl.122S","article-title":"Use of anti-thrombotic agents during pregnancy","volume":"119","author":"Ginsberg","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.beha.2004.03.003_BIB110","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1378\/chest.119.1_suppl.22S","article-title":"Managing oral anti-coagulant therapy","volume":"119","author":"Ansell","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.beha.2004.03.003_BIB111","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anti-coagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB112","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","article-title":"An analysis of the lowest effective intensity of prophylactic anti-coagulation for patients with nonrheumatic atrial fibrillation","volume":"335","author":"Hylek","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB113","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB114","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","article-title":"Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long term prevention of recurrent venous thromboembolism","volume":"349","author":"Kearon","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","article-title":"A randomized trial of anti-coagulants versus aspirin after cerebral ischemia of presumed arterial origin. The stroke prevention in reversible ischemia trial (SPIRIT) study group","volume":"42","year":"1997","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.beha.2004.03.003_BIB116","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)01180-X","article-title":"Randomised double blind trial of fixed low dose warfarin with aspirin after myocardial infarction","volume":"350","year":"1997","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB117","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/hc0502.103329","article-title":"Department of Veterans Affairs cooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study","volume":"105","author":"Fiore","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB118","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial","volume":"348","year":"1996","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB119","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","article-title":"Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial","volume":"360","author":"Van Es","year":"2002","journal-title":"The Lancet"},{"key":"10.1016\/j.beha.2004.03.003_BIB121","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/01.CIR.0000024408.81821.32","article-title":"Aspirin plus coumadin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction. Results of the anti-thrombotics in the prevention of reocclusion in coronary thrombolysis (APRICOT-2) trial","volume":"106","author":"Brouwer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2004.03.003_BIB122","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.282.21.2058","article-title":"Oral anti-coagulant therapy in patients with coronary artery disease: a meta-analysis","volume":"282","author":"Anand","year":"1999","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.beha.2004.03.003_BIB123","series-title":"Anti-coagulants or anti-platelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane review)","author":"Segal","year":"2003"},{"key":"10.1016\/j.beha.2004.03.003_BIB124","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB125","series-title":"Anti-coagulants versus anti-platelet therapy for preventing stroke in patients with non-rheumatic atrial fibrillation and a history of stroke or transient ischemic attacks (Cochrane review)","volume":"3","author":"Koudstaal","year":"2003"},{"key":"10.1016\/j.beha.2004.03.003_BIB126","series-title":"Anti-coagulants for preventing stroke in patients with non-rheumatic atrial fibrillation and a history of stroke or transient ischemic attacks (Cochrane review)","author":"Koudstaal","year":"2003"},{"key":"10.1016\/j.beha.2004.03.003_BIB127","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archinte.157.11.1237","article-title":"The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomised trials","volume":"157","year":"1997","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB128","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archinte.162.8.881","article-title":"Anti-thrombotic treatment and the incidence of angina pectoris","volume":"162","author":"Knottenbelt","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB129","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0735-1097(00)01118-9","article-title":"Effects of long-term, moderate-intensity oral anti-coagulation in addition to aspirin in unstable angina","volume":"37","year":"2001","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199308193290802","article-title":"Comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement","volume":"329","author":"Turpie","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB131","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2003.07.029","article-title":"The optimal intensity of vitamin K antagonists in patients with mechanical heart valves","volume":"42","author":"Vink","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB132","series-title":"Anti-coagulation for heart failure in sinus rhythm (Cochrane review)","author":"Lip","year":"2003"},{"key":"10.1016\/j.beha.2004.03.003_BIB133","series-title":"Anti-coagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack (Cochrane review)","author":"Sandercock","year":"2003"},{"key":"10.1016\/j.beha.2004.03.003_BIB134","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMcp025373","article-title":"Care of patients receiving long-term anti-coagulant therapy","volume":"349","author":"Schulman","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB135","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/hrt.71.2.196","article-title":"Outcome of pregnancy in women with valve prostheses","volume":"71","author":"Sbarouni","year":"1994","journal-title":"British Heart Journal"},{"key":"10.1016\/j.beha.2004.03.003_BIB136","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0735-1097(99)00604-X","article-title":"Atheromas of the thoracic aorta: clinical and therapeutic update","volume":"35","author":"Tunick","year":"2000","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beha.2004.03.003_BIB137","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJM200006293422604","article-title":"Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism","volume":"342","author":"Schulman","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB138","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with anti-phospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB139","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/archinte.163.13.1580","article-title":"Anti-coagulation-related bleeding in older persons with atrial fibrillation","volume":"163","author":"Man-Son-Hing","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB140","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archinte.163.8.901","article-title":"Perioperative management of patients receiving oral anti-coagulants","volume":"163","author":"Dunn","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.003_BIB141","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/bmj.320.7244.1236","article-title":"Prospective cohort study to determine if trial efficacy of anti-coagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness","volume":"320","author":"Kalra","year":"2000","journal-title":"British Medical Journal"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692604000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692604000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T14:59:03Z","timestamp":1705157943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692604000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S1521692604000064"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2004.03.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}